• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Quintiles to acquire Advion BioServices

Quintiles to acquire Advion BioServices

October 26, 2011
CenterWatch Staff

Quintiles has agreed to buy Advion, a 19-year-old bioanalytical lab that recently penned a strategic partnership with Eli Lilly.

Besides adding to Quintiles’ bottom line via the Lilly deal, Advion--which provides Good Laboratory Practice (GLP) pharmacokinetic/pharmacodynamic (PK/PD) testing as well as other services--will help Quintiles fill a hole in its early-stage offerings.

“This acquisition fills in a gap in our capabilities,” said Thomas Wollman, senior vice president of Quintiles Global Laboratories. “As we’ve looked at how we need to grow the business, and at the expectations, needs and requests of our customers, we saw we were short in the bioanalytical area, particularly in metabolomics. This is an additive acquisition.”

Exact terms of the cash deal, which is expected to close this quarter, were undisclosed. Going forward, Advion BioServices will become Advion Bioanalytical Labs, a Quintiles company.

Spun off from Cornell in 1993, Advion has more than 180 employees in three U.S. locations: a 33,000-square-foot GLP bioanalytical laboratory in Ithaca, N.Y. (about 130 employees); a 10,000-square-foot GLP immunoassay laboratory in Manassas, Va. (about 12 employees); and a new, 22,000-square-foot discovery and metabolism lab in Indianapolis (about 40 employees). Advion has worked with 60 different clients in this year alone, according to Quintiles.

Advion co-founders Jack Henion and Tom Kurz, as well as other key members of the management team, will remain on board, said Wollman.

In March of this year, Eli Lilly and Advion formed a multi-year, early-stage bioanalytical outsourcing partnership. The arrangement was a “lift and shift” one, in which Lilly shifted 45 employees to Advion’s new facility in Indianapolis, completed in May, said Wollman.

The partnership was key for Quintiles. “We are very keen to continue that partnership,” said Wollman, who added that Quintiles spoke to executives at Lilly to make sure they were comfortable with the deal.

Why put resources into early phase work right now? Because, said Wollman, the high costs of failure in later-phase trials is causing the industry to shift toward more thorough lab testing in earlier phases.

“It’s the classic trend of drug development where the patent cliff and high R&D costs are putting pressures on companies to find better, deeper information earlier in the process to make better go/no-go decisions,” he said. “Acquiring Advion gives us additional high-science capabilities in key areas in those earlier phases.”

Wollman added that the deal will bring Quintiles 10 Ph.Ds.

Quintiles Global Laboratories works on global and regional trials in almost every country, with wholly owned facilities in the U.S., Europe, South Africa, India, China, Singapore and Japan, and a coordinated network of affiliate laboratories in Argentina and Brazil.

Overall, Quintiles has more than 20,000 employees in 60 countries.

-- Suz Redfearn

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing